Kura Oncology Statistics
Total Valuation
Kura Oncology has a market cap or net worth of $563.31 million. The enterprise value is -$47.94 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kura Oncology has 86.80 million shares outstanding. The number of shares has increased by 7.34% in one year.
| Current Share Class | 86.80M |
| Shares Outstanding | 86.80M |
| Shares Change (YoY) | +7.34% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 0.80% |
| Owned by Institutions (%) | 70.67% |
| Float | 64.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.80 |
| Forward PS | 3.64 |
| PB Ratio | 1.84 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | 4.58 |
| P/OCF Ratio | 4.51 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.16, with a Debt / Equity ratio of 0.06.
| Current Ratio | 6.16 |
| Quick Ratio | 5.93 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.16 |
| Interest Coverage | -138.35 |
Financial Efficiency
Return on equity (ROE) is -51.11% and return on invested capital (ROIC) is -34.00%.
| Return on Equity (ROE) | -51.11% |
| Return on Assets (ROA) | -22.93% |
| Return on Invested Capital (ROIC) | -34.00% |
| Return on Capital Employed (ROCE) | -38.19% |
| Revenue Per Employee | $433,745 |
| Profits Per Employee | -$1.03M |
| Employee Count | 192 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kura Oncology has paid $2.24 million in taxes.
| Income Tax | 2.24M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.81% in the last 52 weeks. The beta is 0.40, so Kura Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -65.81% |
| 50-Day Moving Average | 6.20 |
| 200-Day Moving Average | 8.26 |
| Relative Strength Index (RSI) | 56.38 |
| Average Volume (20 Days) | 1,397,044 |
Short Selling Information
The latest short interest is 7.91 million, so 9.11% of the outstanding shares have been sold short.
| Short Interest | 7.91M |
| Short Previous Month | 8.41M |
| Short % of Shares Out | 9.11% |
| Short % of Float | 12.29% |
| Short Ratio (days to cover) | 6.05 |
Income Statement
In the last 12 months, Kura Oncology had revenue of $83.28 million and -$197.17 million in losses. Loss per share was -$2.26.
| Revenue | 83.28M |
| Gross Profit | -114.83M |
| Operating Income | -219.71M |
| Pretax Income | -181.75M |
| Net Income | -197.17M |
| EBITDA | -218.83M |
| EBIT | -219.71M |
| Loss Per Share | -$2.26 |
Full Income StatementBalance Sheet
The company has $630.73 million in cash and $19.47 million in debt, giving a net cash position of $611.26 million or $7.04 per share.
| Cash & Cash Equivalents | 630.73M |
| Total Debt | 19.47M |
| Net Cash | 611.26M |
| Net Cash Per Share | $7.04 |
| Equity (Book Value) | 305.49M |
| Book Value Per Share | 3.52 |
| Working Capital | 552.90M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $124.99 million and capital expenditures -$2.12 million, giving a free cash flow of $122.87 million.
| Operating Cash Flow | 124.99M |
| Capital Expenditures | -2.12M |
| Free Cash Flow | 122.87M |
| FCF Per Share | $1.42 |
Full Cash Flow StatementMargins
Gross margin is -137.89%, with operating and profit margins of -263.82% and -236.76%.
| Gross Margin | -137.89% |
| Operating Margin | -263.82% |
| Pretax Margin | -234.07% |
| Profit Margin | -236.76% |
| EBITDA Margin | -262.76% |
| EBIT Margin | -263.82% |
| FCF Margin | 147.53% |
Dividends & Yields
Kura Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.34% |
| Shareholder Yield | -7.34% |
| Earnings Yield | -35.00% |
| FCF Yield | 21.81% |
Analyst Forecast
The average price target for Kura Oncology is $24.45, which is 276.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24.45 |
| Price Target Difference | 276.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 73.55% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kura Oncology has an Altman Z-Score of -0.54 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.54 |
| Piotroski F-Score | 3 |